Trial record 7 of 18 for:    gi dynamics

A Study of the GI Sleeve for the Treatment of Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02709577
Recruitment Status : Completed
First Posted : March 16, 2016
Results First Posted : December 28, 2016
Last Update Posted : December 28, 2016
Hospital Dipreca
Information provided by (Responsible Party):
GI Dynamics

Brief Summary:
The purpose of the study was to evaluate the safety and efficacy of the EndoBarrier Gastrointestinal Liner compared to sham control in subjects with Type 2 diabetes.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Device: EndoBarrier Gastrointestinal Liner Other: Sham: endoscopy and standard of care Phase 1 Phase 2

Detailed Description:

The study was designed as a randomized, single blind, sham controlled, pilot efficacy study of subjects with Type 2 diabetes enrolled at 2 centers in Santiago, Chile. Subjects were enrolled at a 2:1 ratio (EndoBarrier to sham). Following implantation or sham procedure, subjects were treated for 24 weeks or 52 weeks. Following explant, subjects were followed for an additional 8-12 weeks.

Subject evaluations included measurements of HbA1c, glucose, insulin, weight, changes in diabetic medications, and meal tolerance tests. Safety was monitored through the collection of clinical labs, physical assessments, endoscopy and adverse events.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Pilot Feasibility Sham Controlled Study of the GI Sleeve for the Treatment of Type 2 Diabetes
Study Start Date : January 2007
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: EndoBarrier Gastrointestinal Liner
Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
Device: EndoBarrier Gastrointestinal Liner
The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
Other Name: GI Sleeve
Experimental: Sham: endoscopy and standard of care
Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
Other: Sham: endoscopy and standard of care
Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
Other Name: Control

Primary Outcome Measures :
  1. Change in HbA1c Values From Baseline Measurement [ Time Frame: Baseline to 24 weeks or 52 weeks ]

    Cohort A: Assessment of improvement in the glycemic control defined as a change in HbA1c values from baseline.

    Cohort B. Assessment of improvement in glycemic control defined as a change in HbA1c values of at least 0.5% from baseline.

Secondary Outcome Measures :
  1. Absolute Weight Change [ Time Frame: 24 weeks or 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years and < 55 years - Male or Female
  • Patients with type 2 diabetes, treated for 10 years or less
  • HbA1c level ≥ 7.0 and ≤ 10.0%
  • Fasting glucose ≤ 240 mg/dl
  • Patients taking metformin, sulfonylureas or thiazolidinediones (TZDs), either alone or in combination
  • BMI > 30 and <50
  • Patients willing to comply with study requirements
  • Patients who have signed an informed consent form
  • Women who are post-menopausal, surgically sterile, or on oral contraceptives for at least three months and who do not plan on becoming pregnant during the course of the study.

Exclusion Criteria:

  • Patients taking oral medications to control their diabetes other than sulfonylureas, metformin or thiazolidinediones
  • Patients diagnosed with type 1 diabetes mellitus or had a history of ketoacidosis
  • Patients requiring insulin
  • Patients with lab evidence of probable insulin production failure (fasting C peptide serum level < 1ng/ml)
  • Patients with a weight loss of > 10 lbs within the three months of screening
  • Patients requiring prescription anticoagulation therapy
  • Patients with iron deficiency and iron deficiency anemia
  • Patients with a history of abnormal pathologies of the GI tract
  • Patients with known gallstones or kidney stones prior to implant
  • Known infection at the time of implant
  • Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
  • Pregnant or has the intention of becoming pregnant in the next 12 months
  • Patients with a history of active kidney stones
  • Mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement or clinical trial
  • Previous GI surgery that could affect the ability to place the sleeve or the function of the implant
  • Patients unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period
  • H. pylori positive patients (Note: patients may be enrolled if they had a prior history and were successfully treated)
  • Patients receiving weight loss medications such as Meridia and Xenical
  • Family or patient history of a known diagnosis or pre-existing symptom of systemic lupus erythematous, scleroderma or other autoimmune connective tissue disorder
  • Patients with Gastrointestinal Reflux Disease (GERD)
  • Participating in another ongoing investigational clinical trial
  • Patients taking corticosteroids or drugs known to affect gastrointestinal motility (such as reglan)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02709577

Sponsors and Collaborators
GI Dynamics
Hospital Dipreca
Principal Investigator: Leonardo Rodriguez Grunert, MD Hospital Dipreca

Responsible Party: GI Dynamics Identifier: NCT02709577     History of Changes
Other Study ID Numbers: 06-5
First Posted: March 16, 2016    Key Record Dates
Results First Posted: December 28, 2016
Last Update Posted: December 28, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases